Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.
Peter A. Riedell, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses the clinical implication of using frontline high-dose rituximab (Rituxan)-based therapy and autologous hematopoietic cell transplantation (AHCT) in patients with mantle cell lymphoma (MCL) in an analysis of time to relapse.
Riedell says this analysis will give researchers a better understanding of patients who relapse after frontline AHCT. There have been data presented in other subtypes of non-Hodgkin’s lymphoma, particularly follicular lymphoma, that gives the researchers in this setting a sense of the timing of relapse and how that may affect outcomes for patients with MCL in the long term.
These data give a better understanding of patients with MCL who relapse early after rituximab and AHCT. In particular, patients who relapsed by the 18-month landmark timepoint after AHCT had a very poor overall survival. These patients likely require different therapeutic approaches in the frontline setting or, more so, in the relapsed setting compared with conventional treatment, according to Riedell. He is talking about treatments such as inclusion in currently enrolling clinical trials or the utilization of chimeric antigen receptor T-cell therapy as novel approaches.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More